Physician profile
Vernesa Wright
NPI 1720577372
$5,655.31
in general payments reported to CMS, 2019-2025
49 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $1,379 · 2023: $1,536 · 2024: $948 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.16 |
| Education | $602.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $535.03 | 2021-2025 | Adcetris, Padcev |
| Janssen Biotech, INC. | $315.64 | 2021-2025 | Rybrevant, Darzalex, Akeega |
| Astellas Pharma US INC | $310.16 | 2023-2025 | Padcev, Xospata, Vyloy |
| Novartis Pharmaceuticals Corporation | $307.35 | 2022-2025 | |
| Incyte Corporation | $306.80 | 2021-2025 | Jakafi |
| Daiichi Sankyo INC. | $302.51 | 2022-2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $285.92 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $264.92 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $254.43 | 2021-2025 | Lynparza, Tagrisso, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $216.44 | 2021-2024 | Ninlaro, Fruzaqla |
| Pfizer INC. | $191.13 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $179.78 | 2022-2025 | Keytruda, Lynparza |
| Abbvie INC. | $173.47 | 2022-2025 | |
| Genentech USA, INC. | $153.32 | 2022-2024 | Polivy, Phesgo, Lunsumio |
| Celgene Corporation | $149.90 | 2022-2025 | Reblozyl |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137.24 | 2021-2023 | Kyprolis, Blincyto |
| Lilly USA, LLC | $121.97 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Apellis Pharmaceuticals, INC. | $118.06 | 2023 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $108.21 | 2022-2025 | |
| Genzyme Corporation | $100.96 | 2023-2025 | |
| Puma Biotechnology, INC. | $98.78 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $89.86 | 2023-2025 | Xpovio |
| Medtronic, INC. | $74.20 | 2024 | Venaseal |
| Glaxosmithkline, LLC. | $66.44 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $60.20 | 2022-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $58.75 | 2023-2024 | Myrisk |
| Array Biopharma INC | $56.92 | 2021-2025 | Braftovi, Tukysa, Mektovi |
| Stemline Therapeutics INC. | $54.18 | 2024-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $48.56 | 2023-2024 | Onivyde, Tazverik |
| Beigene USA, INC. | $47.37 | 2023-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $38.86 | 2022 | |
| Legend Biotech USA INC. | $38.15 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $33.55 | 2023 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.41 | 2023 | Gilotrif |
| Adc Therapeutics America, INC. | $27.87 | 2025 | |
| Beone Medicines USA, INC. | $27.51 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $26.08 | 2024 | Besremi |
| Sobi, INC | $24.96 | 2024 | |
| Exelixis INC. | $24.41 | 2023 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $23.97 | 2023 | Ultomiris |
| Blueprint Medicines Corporation | $23.79 | 2022 | |
| Mirati Therapeutics, INC. | $21.52 | 2023 | Krazati |
| Emd Serono, INC. | $19.07 | 2024 | |
| Foundation Medicine, INC. | $18.80 | 2023 | |
| Immunocore Limited | $18.69 | 2025 | Kimmtrak |
| Eusa Pharma (US) LLC | $18.40 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.56 | 2023 | Pyrukynd |
| Myovant Sciences INC. | $15.75 | 2021 | |
| Coherus Oncology, INC. | $15.46 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernesa Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.